Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00023617.xml
Journal Club AINS 2012; 1(2): 77-79
DOI: 10.1055/s-0033-1333818
DOI: 10.1055/s-0033-1333818
Journal Club
Vasopressin und Terlipressin beim vasodilatatorischen Schock
Further Information
Publication History
Publication Date:
14 January 2013 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00023617/201202/lookinside/thumbnails/10.1055-s-0033-1333818-1.jpg)
Eine wichtige Komponente der Therapie des vasodilatatorischen Schockgeschehens im Rahmen der Intensivmedizin ist der Einsatz von Katecholaminen. Bei prolongierter Anwendung kommt es jedoch zur Wirkungsverminderung durch Abnahme der Rezeptorzahl („Down-Regulation“) und Verminderung der Rezeptorsensibilität (Desensibilisierung). Die Möglichkeit, diesem Effekt durch zusätzliche Gabe von Vasopressin und dessen Analogon Terlipressin entgegenzuwirken, haben Serpa Neto und Kollegen im Rahmen einer Metaanalyse untersucht.
- Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-1125
- Russell J, Walley K, Singer J et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. N Engl J Med 2008; 358: 877-887
- Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327
- Torgersen C, Dunser MW, Schmittinger CA et al. Current approach to the haemodynamic management of septic shock patients in European intensive care units: a cross-sectional, self-reported questionnaire-based survey. Eur J Anaesthesiol 2011; 28: 284-290
- Serpa Neto A, Nassar Junior AP, Cardoso SO et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care 2012; 16
- Luckner G, Dunser MW, Jochberger S et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33: 2659-2666
- Russell JA, Walley KR, Gordon AC et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37: 811-818
- Torgersen C, Luckner G, Schroder DC et al. Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality. Intensive Care Med 2011; 37: 1432-1437
- Torgersen C, Dunser MW, Wenzel V et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010; 36: 57-65
- Rehberg S, Yamamoto Y, Sousse LE et al. Selective V1a agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circ Physiol [Epub ahead of print] 2012;
- Argenziano M, Choudhri AF, Oz MC et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96: 286-290
- Rehberg S, Ertmer C, Vincent JL et al. Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med 2011; 39: 119-125
- Rehberg S, Ertmer C, Kohler G et al. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009; 35: 1286-1296
- Morelli A, Ertmer C, Rehberg S et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009; 13
- Nakada TA, Russell JA, Wellman H et al. Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 2011; 139: 1042-1049